Vincerx Pharma (VINC) Competitors $0.30 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VINC vs. LTRN, DRRX, CLDI, OKYO, LUMO, ELEV, CALC, BLRX, PASG, and LEXXShould you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Lantern Pharma (LTRN), DURECT (DRRX), Calidi Biotherapeutics (CLDI), OKYO Pharma (OKYO), Lumos Pharma (LUMO), Elevation Oncology (ELEV), CalciMedica (CALC), BioLineRx (BLRX), Passage Bio (PASG), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Vincerx Pharma vs. Lantern Pharma DURECT Calidi Biotherapeutics OKYO Pharma Lumos Pharma Elevation Oncology CalciMedica BioLineRx Passage Bio Lexaria Bioscience Vincerx Pharma (NASDAQ:VINC) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation. Does the MarketBeat Community prefer VINC or LTRN? Vincerx Pharma received 9 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote. CompanyUnderperformOutperformVincerx PharmaOutperform Votes2165.63% Underperform Votes1134.38% Lantern PharmaOutperform Votes1275.00% Underperform Votes425.00% Which has more volatility and risk, VINC or LTRN? Vincerx Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Which has higher earnings and valuation, VINC or LTRN? Lantern Pharma is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVincerx PharmaN/AN/A-$40.16M-$1.03-0.29Lantern PharmaN/AN/A-$15.96M-$1.78-1.99 Does the media favor VINC or LTRN? In the previous week, Vincerx Pharma and Vincerx Pharma both had 7 articles in the media. Lantern Pharma's average media sentiment score of 0.51 beat Vincerx Pharma's score of 0.30 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vincerx Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is VINC or LTRN more profitable? Lantern Pharma's return on equity of -56.91% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Vincerx PharmaN/A -248.33% -132.73% Lantern Pharma N/A -56.91%-51.17% Do institutionals & insiders hold more shares of VINC or LTRN? 44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 17.2% of Vincerx Pharma shares are owned by insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend VINC or LTRN? Vincerx Pharma currently has a consensus target price of $2.00, indicating a potential upside of 577.97%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Vincerx Pharma is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVincerx Pharma beats Lantern Pharma on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VINC vs. The Competition Export to ExcelMetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.90M$6.40B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-0.2910.0598.3417.05Price / SalesN/A266.681,206.2271.13Price / CashN/A53.4940.6936.36Price / Book1.099.306.325.87Net Income-$40.16M$154.14M$119.47M$225.66M7 Day Performance-9.87%-9.49%-5.11%-1.34%1 Month Performance-25.88%-7.23%-3.20%1.00%1 Year Performance-59.03%30.70%32.42%25.27% Vincerx Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VINCVincerx Pharma3.0972 of 5 stars$0.30flat$2.00+578.0%-62.0%$9.90MN/A-0.2960Analyst RevisionNews CoverageLTRNLantern Pharma0.8852 of 5 stars$3.53-1.4%N/A-11.7%$38.05MN/A-1.9820Analyst RevisionDRRXDURECT3.2591 of 5 stars$1.21-6.2%N/A+65.6%$37.56M$8.55M-1.9880Analyst ForecastAnalyst RevisionCLDICalidi Biotherapeutics2.4357 of 5 stars$3.38+60.2%N/AN/A$37.55M$50,000.000.0041Earnings ReportNews CoverageGap UpHigh Trading VolumeOKYOOKYO Pharma2.611 of 5 stars$1.10+1.9%N/A-35.9%$37.22MN/A0.007Short Interest ↑LUMOLumos Pharma2.9736 of 5 stars$4.30-1.4%N/A+40.6%$37.20M$2.05M-1.0030Short Interest ↓ELEVElevation Oncology2.0963 of 5 stars$0.62-10.2%N/A+15.0%$36.56MN/A-0.7540Gap UpCALCCalciMedica3.0696 of 5 stars$3.40-2.6%N/A-5.0%$36.55MN/A-2.4330Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeBLRXBioLineRx2.1084 of 5 stars$0.45+4.6%N/A-71.9%$36.29M$4.80M-1.0140Upcoming EarningsAnalyst ForecastShort Interest ↑News CoverageGap UpPASGPassage Bio3.0515 of 5 stars$0.58-13.4%N/A-17.3%$35.95MN/A-0.43130Analyst ForecastNews CoverageLEXXLexaria Bioscience2.3213 of 5 stars$2.26-1.7%N/A+50.0%$35.75M$230,000.00-5.147Upcoming Earnings Related Companies and Tools Related Companies LTRN Competitors DRRX Competitors CLDI Competitors OKYO Competitors LUMO Competitors ELEV Competitors CALC Competitors BLRX Competitors PASG Competitors LEXX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VINC) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this BEFORE November 19th.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredWhat the “Crypto President” means for your moneyDonald Trump has already promised to America's "crypto President"... to bring all bitcoin mining to the USA......Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
